The company acquired select assets of Lenco Diagnostic Laboratories and PathAI Diagnostics in all-cash transactions, totaling $211 million. These acquisitions are included in the DIS business, expanding the company's diagnostic capabilities.

During July 2024, the Company entered into a definitive agreement to acquire all of the outstanding shares of LifeLabs Inc. and all of the partnership interests of BPC Lab Finance LP (collectively "LifeLabs") for a cash purchase price based on a value of approximately C$1.35 billion Canadian Dollars (approximately $985 million U.S. Dollars), including net debt, subject to customary purchase price adjustments. LifeLabs provides laboratory diagnostic information and digital health connectivity systems in Canada.

The Invigorate program includes structured plans to drive savings and improve productivity across the value chain. The company is leveraging automation and artificial intelligence to improve productivity and also improve quality across the entire value chain.

For the six months ended June 30, 2024, the company incurred $27 million of pre-tax charges in connection with restructuring and integration activities, including $14 million of employee separation costs. This indicates management's efforts to streamline operations, but also highlights associated costs.

The effective income tax rate for the three months ended June 30, 2024 was 23.4% compared to 23.5% for the three months ended June 30, 2023. This indicates consistent tax management.

Management, including our Chief Executive Officer and our Chief Financial Officer, concluded that our disclosure controls and procedures were effective as of the end of the period covered by this quarterly report.

The FDA published a final rule to broaden the definition of medical devices to include diagnostic tests and to regulate the laboratories that develop them. The final rule initiates a four-year period for a five-staged process of compliance with medical device regulations, certain FDA quality system requirements and for any required LDT submissions.

Legal challenges have been made to the final rule that may vacate, change, delay or uphold the final rule. The final rule could also impact a revitalization and passage of legislation that authorizes the FDA to regulate LDTs by amending the Food, Drug and Cosmetic Act.

As of June 30, 2024, $1.0 billion remained available under the Company's share repurchase authorization, indicating continued capacity for returning capital to shareholders. However, no shares were repurchased during the six months ended June 30, 2024.

The company estimates capital expenditures of approximately $420 million during 2024, primarily related to investments in laboratory equipment and facilities, including laboratory automations and information technology. This reflects a significant investment in maintaining and upgrading operational infrastructure.

During each of the first and second quarters of 2024, the Company's Board of Directors declared a quarterly cash dividend of $0.75 per common share, demonstrating a commitment to returning value to shareholders.